UPDATE: Citadel Securities Initiates Coverage on Optimer Pharmaceuticals

Citadel Securities has published a report on Optimer Pharmaceuticals initiating coverage on the biopharm company.

In the report, Citadel Securities wrote, "Although we view Dificid as a best-in-class treatment for Clostridium difficile (C. diff) associated infection, we believe competition from less expensive, more established treatment options metronidazole and Vancocin could limit Dificid's peak sales potential. Importantly, we believe cost-sensitive hospital formularies will push Dificid use to only the most severe patients, or those who have failed prior treatments."

Citadel Securities rated Optimer Pharmaceuticals a Neutral with a price target of $10.00. Optimer Pharmaceuticals closed Friday at $8.59.